Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.69 +2.4%	$1.59	$1.03 ▼ $2.41	$52.72M	-0.53	423,646 shs	103,742 shs
CRGX CARGO Therapeutics	$4.54 +1.8%	$4.45	$3.00 ▼ $25.45	$215.71M	0.3	1.74 million shs	1.61 million shs
NLTX Neoleukin Therapeutics	$20.20 -4.3%	$20.39	$2.03 ▼ $14.36	$189.84M	1.11	50,104 shs	168,876 shs
YMAB Y-mAbs Therapeutics	$8.52 +0.1%	$5.30	$3.55 ▼ $16.11	$386.68M	0.57	1.68 million shs	1.10 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	+3.12%	+5.77%	+8.91%	-1.20%	-15.60%
CRGX CARGO Therapeutics	0.00%	-0.45%	-3.25%	+8.25%	-73.00%
NLTX Neoleukin Therapeutics	+9.83%	-0.85%	-5.17%	+8.98%	-38.24%
YMAB Y-mAbs Therapeutics	0.00%	-0.12%	+101.66%	+107.56%	-28.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	2.937 of 5 stars	3.5	5.0	0.0	0.0	2.8	0.0	0.6
CRGX CARGO Therapeutics	2.3563 of 5 stars	2.9	0.0	0.0	0.0	2.7	1.7	1.3
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	2.7677 of 5 stars	2.9	4.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$4.50	166.27% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	239.21% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	1.80	Reduce	$9.62	12.94% Upside

Current Analyst Ratings Breakdown

Latest ATNM, CRGX, YMAB, and NLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$11.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$26.00 ➝ $8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Underperform ➝ Neutral	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$8.60
8/5/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	YMAB Y-mAbs Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2025	YMAB Y-mAbs Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
YMAB Y-mAbs Therapeutics	$87.68M	4.42	N/A	N/A	$1.93 per share	4.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.31	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	N/A
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.50	N/A	N/A	N/A	-26.03%	-24.60%	-18.89%	N/A

Latest ATNM, CRGX, YMAB, and NLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	YMAB Y-mAbs Therapeutics	-$0.27	-$0.07	+$0.20	-$0.07	$18.40 million	$19.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
CRGX CARGO Therapeutics	N/A	12.37	12.37
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
YMAB Y-mAbs Therapeutics	N/A	4.00	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
CRGX CARGO Therapeutics	93.16%
NLTX Neoleukin Therapeutics	52.37%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
CRGX CARGO Therapeutics	2.92%
NLTX Neoleukin Therapeutics	1.58%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
YMAB Y-mAbs Therapeutics	150	45.44 million	36.49 million	Optionable

ATNM, CRGX, YMAB, and NLTX Headlines

Recent News About These Companies

Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock

August 13 at 2:17 AM | insidermonkey.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Posts Earnings Results, Beats Expectations By $0.20 EPS

August 11, 2025 | marketbeat.com

XTX Topco Ltd Purchases 70,686 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 10, 2025 | marketbeat.com

A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast

August 9, 2025 | benzinga.com

Y-mAbs (YMAB) Q2 Revenue Falls 14%

August 9, 2025 | aol.comA

Federated Hermes Inc. Has $680,000 Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

August 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates

August 8, 2025 | zacks.com

Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders

August 8, 2025 | businesswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Brookline Capital Management to Hold

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Cantor Fitzgerald

August 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Lowered to "Hold" at Truist Financial

August 8, 2025 | marketbeat.com

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

August 8, 2025 | globenewswire.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Given Neutral Rating at HC Wainwright

August 8, 2025 | americanbankingnews.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial

August 8, 2025 | americanbankingnews.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

August 7, 2025 | prnewswire.com

Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB

August 7, 2025 | businesswire.com

HC Wainwright Reiterates "Neutral" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

August 7, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call

August 7, 2025 | quiverquant.comQ

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

August 7, 2025 | globenewswire.com

HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)

August 7, 2025 | msn.com

SERB bets on rare cancer drug in $412 million deal for Y-mAbs

August 6, 2025 | thepharmaletter.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATNM, CRGX, YMAB, and NLTX Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.69 +0.04 (+2.42%)

Closing price 04:00 PM Eastern

Extended Trading

$1.68 0.00 (-0.30%)

As of 05:11 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

CARGO Therapeutics NASDAQ:CRGX

$4.54 +0.08 (+1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$4.54 +0.00 (+0.09%)

As of 06:07 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Neoleukin Therapeutics NASDAQ:NLTX

$20.20 -0.91 (-4.31%)

As of 08/14/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Y-mAbs Therapeutics NASDAQ:YMAB

$8.52 +0.01 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$8.52 0.00 (0.00%)

As of 07:01 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time